Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.ortinlabsindia.com | |
Market Cap | 18.95 Cr. | |
Enterprise Value(EV) | 25.56 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -1.09 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.22 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 13.05 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 1.79 | Calculated using Price: 23.30 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.81 Cr. | 8,131,392 Shares |
FaceValue | 10 | |
Company Profile | ||
Ortin Laboratories established in the year 1986 was a private limited company with a nominal capital of Rs 1 lakh to offer quality drugs and medicines to the suffering mankind. Later, in the year 1994, this private limited company converted as a public limited company with 5,060 shareholders which received good subscription from the public. These proceeds were utilised for constructing a factory in a spacious area of 25000 sq feet with all ultra-modern infrastructure as per the WHO GMP Standards to manufacture the complete range of Pharmaceutical Formulations of Tablets, Capsules, Syrups, Dry Powders & Ointments. Due to its concern for quality, the company stands as a leading and predominant pharmaceutical manufacturer of drugs and medicines of the country with turnover running in crores of rupees. |
1 Day |
|
-1.27% |
1 Week |
|
-1.06% |
1 Month |
|
-4.12% |
3 Month |
|
-6.05% |
6 Month |
|
+3.10% |
1 Year |
|
-26.27% |
2 Year |
|
-24.72% |
5 Year |
|
+20.10% |
10 Year |
|
-32.76% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 5.55 | 4.04 | 3.65 | 2.16 | 2.86 | 5.21 | -2.31 | 5.38 | -3.57 | |
Return on Capital Employed (%) | 13.62 | 11.55 | 11.01 | 9.58 | 10.14 | 11.76 | 8.93 | 3.27 | 1.59 | |
Return on Assets (%) | 1.62 | 1.28 | 1.25 | 0.79 | 1.00 | 1.43 | -0.51 | 1.37 | -1.90 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 22 | 22 | 23 | 23 | 24 | 25 | 24 | 11 | 11 | 11 | |
Non Curr. Liab. | 6 | 8 | 16 | 8 | 8 | 8 | 9 | 2 | 2 | 3 | |
Curr. Liab. | 45 | 37 | 27 | 31 | 42 | 72 | 84 | 8 | 8 | 7 | |
Minority Int. | |||||||||||
Equity & Liab. | 73 | 68 | 66 | 62 | 74 | 105 | 117 | 21 | 21 | 20 | |
Non Curr. Assets | 26 | 24 | 35 | 23 | 21 | 23 | 24 | 15 | 15 | 15 | |
Curr. Assets | 47 | 44 | 31 | 38 | 52 | 82 | 92 | 6 | 6 | 5 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 73 | 68 | 66 | 62 | 74 | 105 | 117 | 21 | 21 | 20 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 67 | 60 | 63 | 67 | 80 | 168 | 197 | 8 | 8 | 7 | |
Other Income | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
Total Income | 68 | 61 | 64 | 67 | 80 | 168 | 198 | 8 | 8 | 8 | |
Total Expenditure | -61 | -54 | -57 | -61 | -74 | -162 | -192 | -7 | -8 | -8 | |
PBIDT | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 1 | 1 | 0 | |
Interest | -4 | -4 | -3 | -3 | -3 | -3 | -3 | -1 | -1 | -1 | |
Depreciation | -2 | -2 | -2 | -2 | -2 | -2 | -2 | 0 | 0 | 0 | |
Taxation | -1 | 0 | -1 | -1 | -1 | -1 | 1 | 0 | 0 | ||
Exceptional Items | |||||||||||
PAT | 1 | 1 | 1 | 1 | 1 | 1 | -1 | 1 | 0 | -1 | |
Adjusted EPS | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -2 | -2 | -1 | 1 | 2 | 2 | 7 | 3 | 18 | 2 | |
Cash Fr. Inv. | -2 | 0 | 0 | -1 | -1 | -1 | -3 | -3 | 0 | 0 | |
Cash Fr. Finan. | 5 | 1 | 2 | 0 | -1 | 0 | -3 | -1 | -10 | 0 | |
Net Change | 1 | -1 | 1 | 0 | 0 | 1 | 0 | -1 | 8 | 2 | |
Cash & Cash Eqvt | 2 | 1 | 2 | 2 | -14 | -13 | -13 | -14 | -5 | -4 |
Tue, 31 Jan 2023
Board Meeting Intimation for To Approve Un-Audited Financial Results For The Quarter Ended 31.12.2022 Ortin Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve To approve un-audited financial results for the quarter ended 31.12.2022 |
Fri, 20 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under regulation 74(5) |
Tue, 27 Dec 2022
Closure of Trading Window Closure of trading window for quarter ended 31.12.2022. |
Fri, 03 Feb 2023 |
|
|
|
|
|